克服監管及技術障礙，從中國的生物醫藥增長中受益



70+位來自中國生物製造業的高層決策者

16+ 例以國際最佳實踐為主的深度案例分析

5+ 個小時與您的同行面對面交流

更多！

名來自小分子醫藥製造高層決策者將參加同期舉辦的論壇

以1場活動的價格獲得2場活動的好處！

*Simultaneous translation available at the conference

聆聽生物製藥業高管的見解, 包括：

  • GuangDe-Zhong
    GuangDe Zhong
    President, Quality Association for Pharmaceuticals of Sichuan Province; Former Deputy Director, Sichuan Food and Drug Administration
    Joachim-Walter-Photo
    Dr. Joachim K Walker
    SVP, Biopharmaceutical Operations
    Innobiologics Sdn Bhn
    Allan-Riting-Liu
    Allan Riting Liu, M.D., Ph.D., MBA
    Senior Advisor/Vice President
    Wanbang Biopharmaceutical Group
  • Anita Anita Derks
    Head of Compliance Audit Asia Pacific
    Roche, Australia

    ni-baofu BaoFu Ni
    Vice President Manufacturing
    Genor Biomanufacturing

    Michael-Yu Michael Yu, Ph.D.
    President & CEO
    Innovent Biologics
  • Jian-Dong-Photo-Casual Dong Jian
    Vice President
    Quality Celgen Pharmaceutical

    wu-zhenping Zhenping Wu., Ph.D.
    Senior Vice President, Pharmaceutical Sciences
    Hutchison Medi Pharma

    scott Scott Liu
    President & CEO
    Shanghai Henliusbiotech
  • Su-picture Su Chen
    Chief Executive Officer
    Chengdu Kanghong Biotechnology Company

    Michael-Lee Michael Lee
    Vice President Production
    TDW Pharmaceuticals, Taiwan

    sun-lei Sun Lei
    President, Manufacturing
    AUTEKBIO

生物醫藥行業的面貌已發生了翻天覆地的變化，不管是發展中國家還是新興的市場都取得了長足發展。根據某行業報告，預計到2016年，生物療法將佔全球醫藥市場的23%，銷售額將達1580億美元。。

与化学药品制造相比，生物制药厂商面临更加复杂的工艺和更加严格的监管要求。无论是早期研发还是项目扩产，均需要更好规划、更多投资以及更加精深的技术知识，才能实现理想的结果。

不管貴司還處在早期發展階段、或已形成規模生產或是成熟的國際組織，都可以在2012中國生物製藥工程峰會上得到你想要的所有答案。

Limited complimentary VIP passes are available for manufacturing executives from selected biomanufacturing organisations!

這些高管為什麼選擇在中國生物製藥峰會上發表演講？

I’m interested to attend this conference and share my experience on China’s biosimilars development. I hope that such a platform will bring insights from all the experts and provide great suggestions on strengthening China’s biologics development competencies Allan Riting Liu, M.D., Ph.D., MBA, Senior Advisor/Vice President, Wanbang Biopharmaceutical Group
Innovations and technology are always important driving forces for the biologics industry development. This conference presents a great opportunity to explore available technologies and share best practices. I’m pleased to be part of it and looking forward to contributing my experience. Dr. Joachim K Walter, SVP Biopharmaceutical Operations, Innobiologics Sdn Bhd, Malaysia
Biologic manufacturing and antibody development is a topic dear and near to me. I’m excited to join Biologic Manufacturing China 2012 and meet the great minds around the world to bring forward innovative ideas and insights. Michael Yu, Ph.D., President & CEO, Innovent Biologics

參加2012中國生物製藥峰會，你可以：

  • 聽取全球領先的生物製藥廠商有關上游及下游工藝開發的先進經驗，並藉鑑這些經驗服務於世界一流製造的目標。
  • 學習切實可行的措施來將“質量源於設計”納入到你的生產系統，達到並符合國際質量標準。
  • 清晰地了解生物仿製藥發展的監管要求和技術突破，保持競爭優勢。
  • 揭露生物製藥規模化過程中面臨的挑戰，並尋求解決方法。
  • 以中國及亞洲其他新興市場中其他生物技術製造設備的同行作為基準來了解你所處的位置。
  • 從技術提供商處了解有關細胞發展、發酵和純化工藝創新技術及尖端解決方案的最新動態。
Media Partners
_media